Healios K.K. Share Price

Equities

4593

JP3835100003

Biotechnology & Medical Research

Delayed Japan Exchange 06:11:04 23/04/2024 BST 5-day change 1st Jan Change
153 JPY +4.79% Intraday chart for Healios K.K. +4.08% -7.27%

Financials

Sales 2024 * 910M 5.88M 476M Sales 2025 * 1.38B 8.89M 720M Capitalization 13.16B 85.02M 6.89B
Net income 2024 * -2.69B -17.39M -1.41B Net income 2025 * -2.41B -15.59M -1.26B EV / Sales 2024 * 13.6 x
Net cash position 2024 * 822M 5.31M 430M Net Debt 2025 * 608M 3.93M 318M EV / Sales 2025 * 10 x
P/E ratio 2024 *
-4.4 x
P/E ratio 2025 *
-4.78 x
Employees 64
Yield 2024 *
-
Yield 2025 *
-
Free-Float 62.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.79%
1 week+4.08%
Current month-4.97%
1 month+4.08%
3 months-1.92%
6 months+0.66%
Current year-7.27%
More quotes
1 week
137.00
Extreme 137
155.00
1 month
137.00
Extreme 137
189.00
Current year
114.00
Extreme 114
189.00
1 year
114.00
Extreme 114
332.00
3 years
114.00
Extreme 114
2 557.00
5 years
114.00
Extreme 114
2 557.00
10 years
114.00
Extreme 114
2 669.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 23/02/11
Director of Finance/CFO 47 28/02/18
Chief Tech/Sci/R&D Officer 42 31/03/12
Members of the board TitleAgeSince
Director/Board Member 62 31/12/12
Director/Board Member 71 28/02/18
Chief Executive Officer 47 23/02/11
More insiders
Date Price Change Volume
23/04/24 153 +4.79% 1 174 300
22/04/24 146 +0.69% 455,400
19/04/24 145 0.00% 1,321,400
18/04/24 145 +0.69% 796,700
17/04/24 144 -2.04% 789,200

Delayed Quote Japan Exchange, April 23, 2024 at 06:11 am

More quotes
HEALIOS K.K. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The Company has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
146 JPY
Average target price
280 JPY
Spread / Average Target
+91.78%
Consensus